AstraZeneca will discontinue a certain bottle dosage of its breast cancer drug Truqap (capiversatib) by the end of the year but allow 340B covered entities to replenish their supply with an equivalent dose in blister pack package form.
Louisiana, Health Centers Seek Dismissal of Contract Pharmacy Law Challenge
Attorneys representing the state of Louisiana and 340B providers urged a federal judge to dismiss AstraZeneca’s lawsuit against Louisiana’s contract [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.